Neurotech International Archives | Page 3 of 6 | Cannabiz

Neurotech reports strong trial results as firm raises A$10m to fund drug-registration activities

by Steve Jones April 17, 2024April 18, 2024

Neurotech International (NTI) has raised a further A$10 million through new and existing institutional investors as […]

Neurotech progresses ASD trial, inks deal with contract research organisation

by Martin Lane April 10, 2024July 16, 2024

Company news: Zelira; ECS Botanics; LGP; Ecofibre; Neurotech; Elixinol; Emyria

by Steve Jones and Martin Lane February 28, 2024July 16, 2024

Neurotech’s ASD trial extended by another year

by Martin Lane February 13, 2024July 16, 2024

Company news: Canntic; Myleaf; Neurotech

by Martin Lane January 31, 2024July 11, 2024

Company news: Neurotech; AusCann

by Steve Jones January 25, 2024July 16, 2024

Company news: Cann Global; Cann Group; InhaleRx; AusCann; Wellnex Life; Neurotech; MGC Pharma; Stenocare

by Martin Lane December 4, 2023April 30, 2024

Company news: Emyria; Wellnex Life; Neurotech International; Melodiol Global Health

by Martin Lane November 14, 2023April 30, 2024

Quarterly results: Elixinol; Emyria; Ecofibre; LGP; Bioxyne/BLS; Epsilon; Melodiol; MGC Pharma; AusCann; Neurotech; Wellnex Life; InhaleRx; Cannasouth

by Steve Jones and Martin Lane November 1, 2023November 6, 2023

Neurotech reports positive results from latest trial of cannabinoid drug candidate NTI164

by Martin Lane October 6, 2023April 30, 2024